dupilumab

Tue, 26 Jul 2022 09:41:40 -0400
Dupixent (dupilumab) is indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.